Asthma and Allergic Bronchopulmonary Aspergillosis: Understanding, Insights, and State-of-the-Art - PubMed
4 hours ago
- #ABPA
- #asthma
- #Aspergillus
- Allergic bronchopulmonary aspergillosis (ABPA) is a severe asthma endotype caused by immune responses to Aspergillus fumigatus.
- ABPA is characterized by type 2 immune responses, elevated IgE levels, eosinophilia, and imaging abnormalities like bronchiectasis.
- Genetic predisposition involving HLA genotypes contributes to ABPA susceptibility.
- 2024 guidelines provide standardized criteria for ABPA diagnosis, integrating clinical, immunological, and radiological parameters.
- Management includes anti-inflammatory therapy (corticosteroids) and antifungal therapy (triazoles).
- ABPA has a relapsing-remitting course, requiring systematic monitoring with clinical assessment, IgE levels, and imaging.
- Early diagnosis and treatment are crucial to prevent irreversible lung damage.
- Universal screening of asthma patients for fungal sensitization enables early detection and treatment.
- Future research should focus on precision medicine, novel biomarkers, and inhaled antifungal therapies.